Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) Sees Significant Decline in Short Interest

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) was the recipient of a large drop in short interest in August. As of August 15th, there was short interest totalling 4,000 shares, a drop of 91.4% from the July 31st total of 46,300 shares. Based on an average daily volume of 47,800 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.0% of the company’s stock are short sold.

Theriva Biologics Trading Up 1.8 %

Shares of NYSEAMERICAN TOVX traded up $0.06 during midday trading on Tuesday, reaching $3.36. The company had a trading volume of 65,205 shares, compared to its average volume of 22,156. Theriva Biologics has a 1 year low of $2.66 and a 1 year high of $17.11. The stock has a market cap of $58.06 million, a P/E ratio of -2.92 and a beta of 1.38.

Theriva Biologics (NYSEAMERICAN:TOVX) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($5.50) earnings per share for the quarter.

About Theriva Biologics

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company's lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.